Kawai Megumi, BaMaung Nwe Y, Fidanze Steve D, Erickson Scott A, Tedrow Jason S, Sanders William J, Vasudevan Anil, Park Chang, Hutchins Charles, Comess Kenneth M, Kalvin Douglas, Wang Jieyi, Zhang Qian, Lou Pingping, Tucker-Garcia Lora, Bouska Jennifer, Bell Randy L, Lesniewski Richard, Henkin Jack, Sheppard George S
Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA.
Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7. doi: 10.1016/j.bmcl.2006.03.085. Epub 2006 May 2.
We have screened molecules for inhibition of MetAP2 as a novel approach toward antiangiogenesis and anticancer therapy using affinity selection/mass spectrometry (ASMS) employing MetAP2 loaded with Mn(2+) as the active site metal. After a series of anthranilic acid sulfonamides with micromolar affinities was identified, chemistry efforts were initiated. The micromolar hits were quickly improved to potent nanomolar inhibitors by chemical modifications guided by insights from X-ray crystallography.
我们使用以负载Mn(2+)作为活性位点金属的MetAP2进行亲和选择/质谱分析(ASMS),筛选了用于抑制MetAP2的分子,这是一种抗血管生成和抗癌治疗的新方法。在鉴定出一系列具有微摩尔亲和力的邻氨基苯甲酸磺酰胺后,便开始了化学研究工作。通过X射线晶体学提供的见解指导下的化学修饰,将微摩尔级的活性化合物迅速优化为强效的纳摩尔级抑制剂。